Key result
Cardiac-restricted overexpression of PPARalpha in mice reduced the recovery of cardiac power after ischemia-reperfusion injury compared to nontransgenic controls.
Why the study?
Does chronic activation or deletion of PPARalpha alter cardiac recovery after ischemia-reperfusion injury in isolated mouse hearts?
Does chronic activation or deletion of PPARalpha alter cardiac recovery after ischemia-reperfusion injury in isolated mouse hearts?
Chronic activation of PPARalpha increases fatty acid oxidation and is detrimental to cardiac recovery during reperfusion after ischemia in a mouse model.
Answers are grounded in this paper and cite their sources.
PPARalpha overexpression impairs postischemic recovery in mouse hearts; hypothesis-generating for PPARalpha modulation in clinical ischemia-reperfusion injury.
High fatty acid oxidation (FAO) rates contribute to ischemia-reperfusion injury of the myocardium. Because peroxisome proliferator-activated receptor (PPAR)alpha regulates transcription of several FAO enzymes in the heart, we examined the response of mice with cardiac-restricted overexpression of PPARalpha (MHC-PPARalpha) or whole body PPARalpha deletion including the heart (PPARalpha-/-) to myocardial ischemia-reperfusion injury. Isolated working hearts from MHC-PPARalpha and nontransgenic (NTG) littermates were subjected to no-flow global ischemia followed by reperfusion. MHC-PPARalpha hearts had significantly higher FAO rates during aerobic and postischemic reperfusion (aerobic 1,479 +/- 171 vs. 699 +/- 117, reperfusion 1,062 +/- 214 vs. 601 +/- 70 nmol x g dry wt(-1) x min(-1); P < 0.05) and significantly lower glucose oxidation rates compared with NTG hearts (aerobic 225 +/- 36 vs. 1,563 +/- 165, reperfusion 402 +/- 54 vs. 1,758 +/- 165 nmol x g dry wt(-1) x min(-1); P < 0.05). In hearts from PPARalpha-/- mice, FAO was significantly lower during aerobic and reperfusion (aerobic 235 +/- 36 vs. 442 +/- 75, reperfusion 205 +/- 25 vs. 346 +/- 38 nmol x g dry wt(-1) x min(-1); P < 0.05) whereas glucose oxidation was significantly higher compared with wild-type (WT) hearts (aerobic 2,491 +/- 631 vs. 901 +/- 119, reperfusion 2,690 +/- 562 vs. 1,315 +/- 172 nmol x g dry wt(-1) x min(-1); P < 0.05). Increased FAO rates in MHC-PPARalpha hearts were associated with a markedly lower recovery of cardiac power (45 +/- 9% vs. 71 +/- 6% of preischemic levels in NTG hearts; P < 0.05). In contrast, the percent recovery of cardiac power of PPARalpha-/- hearts was not significantly different from that of WT hearts (80 +/- 8% vs. 75 +/- 9%). This study demonstrates that chronic activation of PPARalpha is detrimental to the cardiac recovery during reperfusion after ischemia.
No takes yet. Share an insight, caveat, or question.
Sambandam et al. (2005) studied Myocardial ischemia-reperfusion injury. Cardiac-restricted overexpression of PPARalpha (MHC-PPARalpha) vs. Nontransgenic (NTG) littermates was evaluated on Recovery of cardiac power (% of preischemic levels) (p=<0.05). Cardiac-restricted overexpression of PPARalpha in mice reduced the recovery of cardiac power after ischemia-reperfusion injury compared to nontransgenic controls.
Synapse has enriched 10 related papers. Consider them for comparative context: